Biopharma Physicians Prescription 
PM360
JULY 21, 2022
As pharma reps’ access to physicians continues to decline, this case study examines the effectiveness of reaching physicians through other means—the EHR. Today’s physicians struggle to balance the increasing demands of patient loads, electronic health record (EHR) systems, and time spent on administrative tasks. THE CHALLENGE.
MedCity News
SEPTEMBER 15, 2024
To realize true, sustainable savings in total cost of care, the healthcare system needs to reconsider the support — or lack of support — it provides throughout patients’ medication experiences and the snowball effect that creates on a lifetime of healthcare costs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JUNE 12, 2017
Market access is influencing drug development and commercial launch strategy more than ever before, with 85% of prescription drugs in the United States reimbursed through managed care plans.
Clarify Health
MAY 19, 2020
There is also a looming, time-sensitive reality that biopharma companies face once their products hit the market: they need to recoup the costs of development as quickly as possible before drug patents expire and generics threaten sales. Which physicians see these patients? sales, medical science liaisons, etc.).
Clarivate
DECEMBER 14, 2021
2021 surveys of patients and physicians in the United States conducted by Clarivate show that: Much of care delivery has gone virtual. Three in five physicians in the United States (60%) report having conducted virtual consultations, as do 35% of patients. physicians; Source: Clarivate, Taking the Pulse(R) U.S.
Clarivate
JULY 5, 2023
biologics market and reduce prescription drug costs. and European physicians across six specialties, and global pipeline analysis curated by experts to provide insights into the evolving landscape. By end of year, as many as ten adalimumab biosimilars could be on the U.S. In 2022, it made its manufacturer, AbbVie, $21.2bn.
Clarivate
OCTOBER 25, 2023
While more expensive than type 2 diabetes drugs, blood thinners follow a similar pattern of high prescription volumes. In both cases, a shift in formulary placement could lower prescription volumes and reduce member utilization. With 27.5% exclusions exist for orphan drug designation and biosimilar competition ).
Expert insights. Personalized for you.
52 
Let's personalize your content